Nobody in the medical technology sector has exactly been doing handsprings over the past few years, as lower patient visit volumes, reimbursement pressure, regulatory changes and sharply lower capital spending have all conspired to keep this supposedly-safe sector mired in the muck. Worst off of all, though, have been those companies that depend upon big-ticket capital equipment sales.
IN PICTURES: Eight Ways To Survive A Market Downturn

Radiation therapy is a classic healthcare capital equipment sub-sector. The machinery built to deliver radiotherapy for cancer patients is incredibly expensive; sometimes the most expensive equipment a hospital will consider in any given time period. Although it is far too early to say that the sector is out of the woods, there are certainly some signs of life in the sector and investors may want to bone up on some of the major names.

Varian (NYSE:VAR) is the big dog in the sector and has a long history of improving profit margins and excellent returns on capital. Varian already has more than two-thirds of the U.S. market for radiation therapy systems, and a sizable share outside the U.S. as well. Not content to rest on its laurels, the company continues to roll out new products, like the recently-released TrueBeam system.

TomoTherapy (Nasdaq:TOMO) ran into a bad capital equipment market just at the wrong time. While the company's initial Hi-Art product was a big step forward with its integrated imaging, 360-degree delivery and treatment times, the slowdown (or shutdown, in some cases) of orders in the sector really took the wind of the company's sails. Instead of gaining a solid foothold in the sector on the basis of its technology, the company instead was forced to muddle through an industry that hit "pause", during which its competitors begin to catch up in terms of some product features. (For more, see A Checklist For Successful Medical Technology Investment.)

There is a big opportunity outside the U.S. for image-guided radiation therapy, and the company's new TomoHD product should improve the company's competitive position. At the same time, though, the company has had difficulty marketing against industry leaders like Varian and Elekta. While TOMO is seeing a recovery in orders, this company may be one to watch for getting bid from a larger company like Philips (NYSE:PHG) or General Electric (NYSE:GE) that wants to move from imaging into therapy delivery.

Siemens is a somewhat-distant third place in the radiation therapy business after Varian and Elekta. As many investors probably know, Siemens is a widely diversified company with a business model somewhat similar to GE - in other words, radiation therapy is not a huge segment of Siemens' business. That said, Siemens looks to be getting more serious about this niche - there are rumors that the company is considering spinning it out and the company has been making a fair bit of noise about rolling out new product lines that can go head-to-head with Varian, TomoTherapy and Elekta.

Accuray (Nasdaq:ARAY) is the platypus of this group - it is not exactly a radiation therapy company, but it does not fit anywhere else any better. Accuray sells the CyberKnife and dominates the stereotactic radiosurgery market. While systems from Varian and TomoTherapy generally deliver moderate doses of radiation over a general area in a number of sessions, the CyberKnife is more like a surgical device in that it delivers a very high, concentrated, and precisely-focused dose that is designed to destroy the tumor quickly (like surgery).

IN PICTURES: 20 Tools For Building Up Your Portfolio

While Varian and TomoTherapy systems can be used in radiosurgery, the CyberKnife is custom-built for it and does the job well. Accuray's technology and products were interesting enough to attract Siemens attention, and the two companies recently formed a partnership whereby Siemens will market the CyberKnife and Accuray will produce some components for Siemens' new linear accelerators for the radiotherapy market.

Elekta may be last, but it is by no means least. Elekta is the number two company in the industry, with a strong business in Europe. As a Swedish company with an illiquid ADR, it is not an investable stock for most investors. Still, it is a formidable competitor to these other investable names and investors should keep in mind that Elekta's Volumetric Arc Therapy has narrowed some of TomoTherapy's advantages in the market.

The Bottom Line
It may be time for radiation therapy companies to get off the mat. A horrible hospital CAPEX environment is slowly improving (and cancer therapy tends to be a budget priority) and the sector escaped some potentially scary Medicare cuts. Varian has already had a decent rebound, but risk-tolerant investors may want to take a long look at TomoTherapy and Accuray as both have struggled to recapture investor optimism.

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Stock Analysis

    Fortinet: A Great Play on Cybersecurity

    Discover how a healthy product mix, large-business deal growth and the boom of the cybersecurity industry are all driving Fortinet profits.
  2. Stock Analysis

    2 Catalysts Driving Intrexon to All-Time Highs

    Examine some of the main reasons for Intrexon stock tripling in price between 2014 and 2015, and consider the company's future prospects.
  3. Stock Analysis

    Net Neutrality: Pros and Cons

    The fight over net neutrality has become an amazing spectacle. But at its core, it's yet another skirmish in cable television's war to remain relevant.
  4. Charts & Patterns

    Understand How Square Works before the IPO

    Square is reported to have filed for an IPO. For interested investors wondering how the company makes money, Investopedia takes a look at its business.
  5. Technical Indicators

    4 Ways to Find a Penny Stock Worth Millions

    Thinking of trading in risky penny stocks? Use this checklist to find bargains, not scams.
  6. Professionals

    Chinese Slowdown Affects Iron Ore Market

    The Chinese economy's ongoing slowdown is having a major impact on iron ore demand.
  7. Investing Basics

    Why do Debt to Equity Ratios Vary From Industry to Industry?

    Obtain a better understanding of the debt/equity ratio, and learn why this fundamental financial metric varies significantly between industries.
  8. Personal Finance

    A Day in the Life of an Equity Research Analyst

    What does an equity research analyst do on an everyday basis?
  9. Mutual Funds & ETFs

    ETF Analysis: PowerShares S&P 500 Downside Hedged

    Find out about the PowerShares S&P 500 Downside Hedged ETF, and learn detailed information about characteristics, suitability and recommendations of it.
  10. Mutual Funds & ETFs

    ETF Analysis: iShares Morningstar Small-Cap Value

    Find out about the Shares Morningstar Small-Cap Value ETF, and learn detailed information about this exchange-traded fund that focuses on small-cap equities.
  1. Equity

    The value of an asset less the value of all liabilities on that ...
  2. Profit Margin

    A category of ratios measuring profitability calculated as net ...
  3. Quarter - Q1, Q2, Q3, Q4

    A three-month period on a financial calendar that acts as a basis ...
  4. Debt Ratio

    A financial ratio that measures the extent of a company’s or ...
  5. Price-Earnings Ratio - P/E Ratio

    The Price-to-Earnings Ratio or P/E ratio is a ratio for valuing ...
  6. Net Present Value - NPV

    The difference between the present values of cash inflows and ...
  1. What is the formula for calculating compound annual growth rate (CAGR) in Excel?

    The compound annual growth rate, or CAGR for short, measures the return on an investment over a certain period of time. Below ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. When does the fixed charge coverage ratio suggest that a company should stop borrowing ...

    Since the fixed charge coverage ratio indicates the number of times a company is capable of making its fixed charge payments ... Read Full Answer >>
  4. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  5. What is the difference between the return on total assets and an interest rate?

    Return on total assets (ROTA) represents one of the profitability metrics. It is calculated by taking a company's earnings ... Read Full Answer >>
  6. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>

You May Also Like

Trading Center

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!